KUAISHOU

KUAISHOU 01024.HK Price

KUAISHOU
$0
+$0(%0,00)
No data

*Data last updated: 2026-04-13 09:15 (UTC+8)

As of 2026-04-13 09:15, KUAISHOU 01024.HK (KUAISHOU) is priced at $0, with a total market cap of --, a P/E ratio of 0,00, and a dividend yield of %0,00. Today, the stock price fluctuated between $0 and $0. The current price is %0,00 above the day's low and %0,00 below the day's high, with a trading volume of --. Over the past 52 weeks, KUAISHOU has traded between $0 to $0, and the current price is %0,00 away from the 52-week high.

KUAISHOU Key Stats

P/E Ratio0,00
Dividend Yield (TTM)%0,00
Shares Outstanding0,00

KUAISHOU 01024.HK (KUAISHOU) FAQ

What's the stock price of KUAISHOU 01024.HK (KUAISHOU) today?

x
KUAISHOU 01024.HK (KUAISHOU) is currently trading at $0, with a 24h change of %0,00. The 52-week trading range is $0–$0.

What are the 52-week high and low prices for KUAISHOU 01024.HK (KUAISHOU)?

x

What is the price-to-earnings (P/E) ratio of KUAISHOU 01024.HK (KUAISHOU)? What does it indicate?

x

What is the market cap of KUAISHOU 01024.HK (KUAISHOU)?

x

What is the most recent quarterly earnings per share (EPS) for KUAISHOU 01024.HK (KUAISHOU)?

x

Should you buy or sell KUAISHOU 01024.HK (KUAISHOU) now?

x

What factors can affect the stock price of KUAISHOU 01024.HK (KUAISHOU)?

x

How to buy KUAISHOU 01024.HK (KUAISHOU) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

Hot Posts About KUAISHOU 01024.HK (KUAISHOU)

GateUser-bd883c58

GateUser-bd883c58

1 hours ago
Ask AI · Can the recovery trend continue after bad news for Hong Kong stocks is fully priced in? As of the close on April 1, the Hang Seng Index in Hong Kong rose 2.04% to 25,294.03 points, the Hang Seng Tech Index rose 2.29% to 4,756.45 points, the State-owned Enterprises Index rose 1.56% to 8,504.81 points, and the Red Chip Index rose 1.37% to 4,176.39 points. The biopharmaceutical sector led the gains, with Rongchang Biotech up more than 15%, Innovent Biologics up more than 11%, and BeiGene up more than 7%. Chip stocks strengthened, with H3C (Huahong Semiconductor) up more than 7%, GigaDevice Semiconductor up more than 6%, and SMIC up more than 4%. Gold stocks broadly rose, with Lingbao Gold up more than 10% and China Gold International up more than 7%. Oil and gas stocks fell, with Shandong Molong down more than 8% and CNOOC down more than 3%. Among large tech stocks, Alibaba-W rose 3.11%, Tencent Holdings rose 2.6%, JD.com-SW fell 0.27%, Xiaomi Group-W rose 0.82%, NetEase-S rose 3.28%, Meituan-W fell 1.21%, Kuaishou-W rose 2.39%, and Bilibili-W rose 6.97%. **Brokerage Opinions:** China Galaxy: Hong Kong stocks are entering a window where bad news is fully priced in China Galaxy said that Hong Kong stocks are entering a window where bad news is fully priced in. If external risks do not further worsen, the market is expected to continue the recovery trend under a “resonance” effect driven by the execution of unlockings, earnings verification, and capital returning to the market. The peak of unlockings in March formed a short-term negative factor, but this pressure is now being implemented and digested. The decline in the unlocking scale in the second quarter may become an opportunity to clear negative sentiment. As of March 28, 2026, the market value of Hong Kong stocks unlocked in March was HKD 88.83 billion, up 264.02% year over year. The market value of Hong Kong stocks with market caps exceeding HKD 10 billion that were unlocked in the first quarter was HKD 186.255 billion, up 637.05% year over year. After unlocking pressure is released, sentiment is expected to recover. For high-quality companies with strong fundamentals, if unlockings trigger irrational declines, it may instead provide a window for medium- to long-term positioning. Guosheng Securities: China’s innovative drug R&D has entered a high-quality harvest period Guosheng Securities’ research report believes that clinical activity continues to improve, and China’s innovative drug R&D has entered a high-quality harvest period. By the end of 2025, the global share of the number of innovative drugs in development by Chinese companies reached 33.7%, ranking first worldwide. In 2025, there were 827 original innovative drugs from China that entered clinical trials for the first time, with a global share of 47.4%. Meanwhile, in 2025, China approved and listed 76 innovative drugs, hitting a historic high. Domestic innovative drugs are gradually entering a high-quality harvest period.
0
0
0
0